Anticipate generic drug launch
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Manage your formulary budget
|Title:||DDAVP antidiuretic and method therefor|
|Abstract:||There is disclosed, in one aspect, an antidiuretic composition in oral dosage form for humans. This composition comprises an antidiuretically effective amount of 1-deamino-8-D-arginine vasopressin (DDAVP) and a pharmaceutically acceptable carrier. The composition is capable of dissolving and being absorbed in the gastrointestinal tract of a human. The composition isused in tablet, capsule, or other generally accepted oral dosage form and generally from about 50 to about 200 micrograms of DDAVP is used per unit dosage In another aspect, there is disclosed a method for treating diabetes insipidus. This method comprises orally administering an antidiuretically effective amount of DDAVP to a human. The DDAVP is substantially dissolved and absorbed in the gastrointestinal tract of the person so treated.|
|Inventor(s):||Hagstam; Helmer (Malmo, SE), Vilhardt; Hans (Espergarde, DK)|
|Assignee:||Ferring B.V. (Haarlen, NL)|
Patent Claim Types:|
see list of patent claims
|Composition; Compound; Dosage form; Use;|
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Sweden||8306367||Nov 18, 1983|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.